INS and Cirrhosis: SGLT2i offer a biologically coherent and clinically promising adjunct to standard care for cirrhosis, particularly in patients with ascites, by coupling insulin-independent glycosuria with natriuresis, partial restoration of tubuloglomerular feedback and preferential interstitial fluid mobilization.